Positive results from the global COAST 1 phase 3 study (clinical study identifier: NCT06130566) showed that amlitelimab, a fully human non-T cell depleting monoclonal antibody that targets OX40-ligand ...
Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, ...
Some might say it looks like a finger. Others might see a worm. Scientists in the field often liken it to an antenna. The technical name is primary cilium. This slender, microscopic appendage juts out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback